Catalytic competence, structure and stability of the cancer-associated R139W variant of the human NAD(P)H: quinone oxidoreductase 1 (NQO1)

Wolf Dieter Lienhart, Emilia Strandback, Venugopal Gudipati, Karin Koch, Alexandra Binter, Michael K. Uhl, David M. Rantasa, Benjamin Bourgeois, Tobias Madl, Klaus Zangger, Karl Gruber, Peter Macheroux

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The human NAD(P)H:quinone oxidoreductase 1 (NQO1; EC1.6.99.2) is an essential enzyme in the antioxidant defence system. Furthermore, NQO1 protects tumour suppressors like p53, p33ING 1b and p73 from proteasomal degradation. The activity of NQO1 is also exploited in chemotherapy for the activation of quinone-based treatments. Various single nucleotide polymorphisms are known, such as NQO1*2 and NQO1*3 yielding protein variants of NQO1 with single amino acid replacements, i.e. P187S and R139W, respectively. While the former NOQ1 variant is linked to a higher risk for specific kinds of cancer, the role, if any, of the arginine 139 to tryptophan exchange in disease development remains obscure. On the other hand, mitomycin C-resistant human colon cancer cells were shown to harbour the NQO1*3 variant resulting in substantially reduced enzymatic activity. However, the molecular cause for this decrease remains unclear. In order to resolve this issue, recombinant NQO1 R139W has been characterized biochemically and structurally. In this report, we show by X-ray crystallography and 2D-NMR spectroscopy that this variant adopts the same structure both in the crystal as well as in solution. Furthermore, the kinetic parameters obtained for the variant are similar to those reported for the wild-type protein. Similarly, thermostability of the variant was only slightly affected by the amino acid replacement. Therefore, we conclude that the previously reported effects in human cancer cells cannot be attributed to protein stability or enzyme activity. Instead, it appears that loss of exon 4 during maturation of a large fraction of pre-mRNA is the major reason of the observed lack of enzyme activity and hence reduced activation of quinone-based chemotherapeutics.

Original languageEnglish
Pages (from-to)1233-1245
Number of pages13
JournalFEBS Journal
Volume284
Issue number8
DOIs
Publication statusPublished - 1 Apr 2017

Fingerprint

Mental Competency
Enzyme activity
Enzymes
Chemical activation
Cells
Amino Acids
Neoplasms
Proteins
Chemotherapy
Protein Stability
X ray crystallography
X Ray Crystallography
RNA Precursors
Mitomycin
Ports and harbors
Polymorphism
Kinetic parameters
Tryptophan
Colonic Neoplasms
Nuclear magnetic resonance spectroscopy

Keywords

  • cancer
  • crystal structure
  • enzyme kinetics
  • microcalorimetry
  • NMR-spectroscopy
  • single nucleotide polymorphism

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Catalytic competence, structure and stability of the cancer-associated R139W variant of the human NAD(P)H : quinone oxidoreductase 1 (NQO1). / Lienhart, Wolf Dieter; Strandback, Emilia; Gudipati, Venugopal; Koch, Karin; Binter, Alexandra; Uhl, Michael K.; Rantasa, David M.; Bourgeois, Benjamin; Madl, Tobias; Zangger, Klaus; Gruber, Karl; Macheroux, Peter.

In: FEBS Journal, Vol. 284, No. 8, 01.04.2017, p. 1233-1245.

Research output: Contribution to journalArticleResearchpeer-review

Lienhart, WD, Strandback, E, Gudipati, V, Koch, K, Binter, A, Uhl, MK, Rantasa, DM, Bourgeois, B, Madl, T, Zangger, K, Gruber, K & Macheroux, P 2017, 'Catalytic competence, structure and stability of the cancer-associated R139W variant of the human NAD(P)H: quinone oxidoreductase 1 (NQO1)' FEBS Journal, vol. 284, no. 8, pp. 1233-1245. https://doi.org/10.1111/febs.14051
Lienhart, Wolf Dieter ; Strandback, Emilia ; Gudipati, Venugopal ; Koch, Karin ; Binter, Alexandra ; Uhl, Michael K. ; Rantasa, David M. ; Bourgeois, Benjamin ; Madl, Tobias ; Zangger, Klaus ; Gruber, Karl ; Macheroux, Peter. / Catalytic competence, structure and stability of the cancer-associated R139W variant of the human NAD(P)H : quinone oxidoreductase 1 (NQO1). In: FEBS Journal. 2017 ; Vol. 284, No. 8. pp. 1233-1245.
@article{6287ae7e68b04d1e85bb2855b7c4c45c,
title = "Catalytic competence, structure and stability of the cancer-associated R139W variant of the human NAD(P)H: quinone oxidoreductase 1 (NQO1)",
abstract = "The human NAD(P)H:quinone oxidoreductase 1 (NQO1; EC1.6.99.2) is an essential enzyme in the antioxidant defence system. Furthermore, NQO1 protects tumour suppressors like p53, p33ING 1b and p73 from proteasomal degradation. The activity of NQO1 is also exploited in chemotherapy for the activation of quinone-based treatments. Various single nucleotide polymorphisms are known, such as NQO1*2 and NQO1*3 yielding protein variants of NQO1 with single amino acid replacements, i.e. P187S and R139W, respectively. While the former NOQ1 variant is linked to a higher risk for specific kinds of cancer, the role, if any, of the arginine 139 to tryptophan exchange in disease development remains obscure. On the other hand, mitomycin C-resistant human colon cancer cells were shown to harbour the NQO1*3 variant resulting in substantially reduced enzymatic activity. However, the molecular cause for this decrease remains unclear. In order to resolve this issue, recombinant NQO1 R139W has been characterized biochemically and structurally. In this report, we show by X-ray crystallography and 2D-NMR spectroscopy that this variant adopts the same structure both in the crystal as well as in solution. Furthermore, the kinetic parameters obtained for the variant are similar to those reported for the wild-type protein. Similarly, thermostability of the variant was only slightly affected by the amino acid replacement. Therefore, we conclude that the previously reported effects in human cancer cells cannot be attributed to protein stability or enzyme activity. Instead, it appears that loss of exon 4 during maturation of a large fraction of pre-mRNA is the major reason of the observed lack of enzyme activity and hence reduced activation of quinone-based chemotherapeutics.",
keywords = "cancer, crystal structure, enzyme kinetics, microcalorimetry, NMR-spectroscopy, single nucleotide polymorphism",
author = "Lienhart, {Wolf Dieter} and Emilia Strandback and Venugopal Gudipati and Karin Koch and Alexandra Binter and Uhl, {Michael K.} and Rantasa, {David M.} and Benjamin Bourgeois and Tobias Madl and Klaus Zangger and Karl Gruber and Peter Macheroux",
year = "2017",
month = "4",
day = "1",
doi = "10.1111/febs.14051",
language = "English",
volume = "284",
pages = "1233--1245",
journal = "The FEBS journal",
issn = "1742-464X",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Catalytic competence, structure and stability of the cancer-associated R139W variant of the human NAD(P)H

T2 - quinone oxidoreductase 1 (NQO1)

AU - Lienhart, Wolf Dieter

AU - Strandback, Emilia

AU - Gudipati, Venugopal

AU - Koch, Karin

AU - Binter, Alexandra

AU - Uhl, Michael K.

AU - Rantasa, David M.

AU - Bourgeois, Benjamin

AU - Madl, Tobias

AU - Zangger, Klaus

AU - Gruber, Karl

AU - Macheroux, Peter

PY - 2017/4/1

Y1 - 2017/4/1

N2 - The human NAD(P)H:quinone oxidoreductase 1 (NQO1; EC1.6.99.2) is an essential enzyme in the antioxidant defence system. Furthermore, NQO1 protects tumour suppressors like p53, p33ING 1b and p73 from proteasomal degradation. The activity of NQO1 is also exploited in chemotherapy for the activation of quinone-based treatments. Various single nucleotide polymorphisms are known, such as NQO1*2 and NQO1*3 yielding protein variants of NQO1 with single amino acid replacements, i.e. P187S and R139W, respectively. While the former NOQ1 variant is linked to a higher risk for specific kinds of cancer, the role, if any, of the arginine 139 to tryptophan exchange in disease development remains obscure. On the other hand, mitomycin C-resistant human colon cancer cells were shown to harbour the NQO1*3 variant resulting in substantially reduced enzymatic activity. However, the molecular cause for this decrease remains unclear. In order to resolve this issue, recombinant NQO1 R139W has been characterized biochemically and structurally. In this report, we show by X-ray crystallography and 2D-NMR spectroscopy that this variant adopts the same structure both in the crystal as well as in solution. Furthermore, the kinetic parameters obtained for the variant are similar to those reported for the wild-type protein. Similarly, thermostability of the variant was only slightly affected by the amino acid replacement. Therefore, we conclude that the previously reported effects in human cancer cells cannot be attributed to protein stability or enzyme activity. Instead, it appears that loss of exon 4 during maturation of a large fraction of pre-mRNA is the major reason of the observed lack of enzyme activity and hence reduced activation of quinone-based chemotherapeutics.

AB - The human NAD(P)H:quinone oxidoreductase 1 (NQO1; EC1.6.99.2) is an essential enzyme in the antioxidant defence system. Furthermore, NQO1 protects tumour suppressors like p53, p33ING 1b and p73 from proteasomal degradation. The activity of NQO1 is also exploited in chemotherapy for the activation of quinone-based treatments. Various single nucleotide polymorphisms are known, such as NQO1*2 and NQO1*3 yielding protein variants of NQO1 with single amino acid replacements, i.e. P187S and R139W, respectively. While the former NOQ1 variant is linked to a higher risk for specific kinds of cancer, the role, if any, of the arginine 139 to tryptophan exchange in disease development remains obscure. On the other hand, mitomycin C-resistant human colon cancer cells were shown to harbour the NQO1*3 variant resulting in substantially reduced enzymatic activity. However, the molecular cause for this decrease remains unclear. In order to resolve this issue, recombinant NQO1 R139W has been characterized biochemically and structurally. In this report, we show by X-ray crystallography and 2D-NMR spectroscopy that this variant adopts the same structure both in the crystal as well as in solution. Furthermore, the kinetic parameters obtained for the variant are similar to those reported for the wild-type protein. Similarly, thermostability of the variant was only slightly affected by the amino acid replacement. Therefore, we conclude that the previously reported effects in human cancer cells cannot be attributed to protein stability or enzyme activity. Instead, it appears that loss of exon 4 during maturation of a large fraction of pre-mRNA is the major reason of the observed lack of enzyme activity and hence reduced activation of quinone-based chemotherapeutics.

KW - cancer

KW - crystal structure

KW - enzyme kinetics

KW - microcalorimetry

KW - NMR-spectroscopy

KW - single nucleotide polymorphism

UR - http://www.scopus.com/inward/record.url?scp=85017371738&partnerID=8YFLogxK

U2 - 10.1111/febs.14051

DO - 10.1111/febs.14051

M3 - Article

VL - 284

SP - 1233

EP - 1245

JO - The FEBS journal

JF - The FEBS journal

SN - 1742-464X

IS - 8

ER -